With FDA filing for key gene therapy pushed back 6 months, uniQure opens the pocketbook to refresh the pipeline
Once facing a major setback for its lead gene therapy program for hemophilia B, uniQure saw a sliver of light when the FDA lifted a lengthy clinical hold earlier this year. Now, the biotech is feeling bullish enough to add some new blood into its pipeline even as its lead therapy continues to face new hurdles.
UniQure will spend $55 million upfront with the potential for nearly $240 million in downstream milestones for shareholders to acquire EU biotech Corlieve Therapeutics and its lead gene therapy, dubbed AMT-260, for temporal lobe epilepsy, the partners said Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
